These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 28947392)

  • 1. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
    Gregory MA; Nemkov T; Reisz JA; Zaberezhnyy V; Hansen KC; D'Alessandro A; DeGregori J
    Exp Hematol; 2018 Feb; 58():52-58. PubMed ID: 28947392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia.
    Gregory MA; D'Alessandro A; Alvarez-Calderon F; Kim J; Nemkov T; Adane B; Rozhok AI; Kumar A; Kumar V; Pollyea DA; Wempe MF; Jordan CT; Serkova NJ; Tan AC; Hansen KC; DeGregori J
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6669-E6678. PubMed ID: 27791036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
    Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
    Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
    Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
    Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
    Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.
    Hou P; Wu C; Wang Y; Qi R; Bhavanasi D; Zuo Z; Dos Santos C; Chen S; Chen Y; Zheng H; Wang H; Perl A; Guo D; Huang J
    Cancer Res; 2017 Aug; 77(16):4402-4413. PubMed ID: 28625976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
    Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
    Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.
    Hirade T; Abe M; Onishi C; Taketani T; Yamaguchi S; Fukuda S
    Int J Hematol; 2016 Jan; 103(1):95-106. PubMed ID: 26590920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.
    Staffas A; Arabanian LS; Wei SY; Jansson A; Ståhlman S; Johansson P; Fogelstrand L; Cammenga J; Kuchenbauer F; Palmqvist L
    Oncogene; 2017 Mar; 36(11):1516-1524. PubMed ID: 27617578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
    Keegan K; Li C; Li Z; Ma J; Ragains M; Coberly S; Hollenback D; Eksterowicz J; Liang L; Weidner M; Huard J; Wang X; Alba G; Orf J; Lo MC; Zhao S; Ngo R; Chen A; Liu L; Carlson T; Quéva C; McGee LR; Medina J; Kamb A; Wickramasinghe D; Dai K
    Mol Cancer Ther; 2014 Apr; 13(4):880-9. PubMed ID: 24526162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
    Xu B; Zhao Y; Wang X; Gong P; Ge W
    Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quizartinib (AC220): a promising option for acute myeloid leukemia.
    Zhou F; Ge Z; Chen B
    Drug Des Devel Ther; 2019; 13():1117-1125. PubMed ID: 31114157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes.
    An X; Liu J; Wang N; Wang D; Huang L; Zhang L; Cai J; Wery JP; Zhou D; Zhou J; Li QX
    Exp Hematol; 2017 Jan; 45():36-44.e2. PubMed ID: 27670587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia.
    Liu LL; Zhang DH; Mao X; Zhang XH; Zhang B
    Biochem Biophys Res Commun; 2014 Mar; 446(1):280-5. PubMed ID: 24582753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
    Zarrinkar PP; Gunawardane RN; Cramer MD; Gardner MF; Brigham D; Belli B; Karaman MW; Pratz KW; Pallares G; Chao Q; Sprankle KG; Patel HK; Levis M; Armstrong RC; James J; Bhagwat SS
    Blood; 2009 Oct; 114(14):2984-92. PubMed ID: 19654408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia.
    Gebru MT; Atkinson JM; Young MM; Zhang L; Tang Z; Liu Z; Lu P; Dower CM; Chen L; Annageldiyev C; Sharma A; Imamura Kawasawa Y; Zhao Z; Miller BA; Claxton DF; Wang HG
    Blood; 2020 Aug; 136(9):1067-1079. PubMed ID: 32396937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
    Smith CC; Wang Q; Chin CS; Salerno S; Damon LE; Levis MJ; Perl AE; Travers KJ; Wang S; Hunt JP; Zarrinkar PP; Schadt EE; Kasarskis A; Kuriyan J; Shah NP
    Nature; 2012 Apr; 485(7397):260-3. PubMed ID: 22504184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Glutamine Metabolism and Redox State for Leukemia Therapy.
    Gregory MA; Nemkov T; Park HJ; Zaberezhnyy V; Gehrke S; Adane B; Jordan CT; Hansen KC; D'Alessandro A; DeGregori J
    Clin Cancer Res; 2019 Jul; 25(13):4079-4090. PubMed ID: 30940653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220.
    Pauwels D; Sweron B; Cools J
    Haematologica; 2012 Nov; 97(11):1773-4. PubMed ID: 22875611
    [No Abstract]   [Full Text] [Related]  

  • 20. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.